Development and characterization of functionalized niosomes for brain targeting of dynorphin-B

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 87, Issue 1, 2014, Pages 73-79

  Bragagni, M ^a   Mennini, N ^a   Furlanetto, S ^a   Orlandini, S ^a   Ghelardini, C ^a   Mura, P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Brain targeting; Design of experiments; Dynorphin B; Glucose bearing niosomes; Hot plate latency test; Response surface study

Indexed keywords

DYNORPHIN B; NIOSOME; SORBITAN STEARATE; ANALGESIC AGENT; DRUG CARRIER; DYNORPHIN; ENDORPHIN; GLYCOLIPID; KAPPA OPIATE RECEPTOR; LIPOSOME; N-PALMITOYLGLUCOSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG FORMULATION; HOT PLATE TEST; MALE; MATHEMATICAL MODEL; MEMBRANE VESICLE; MOUSE; NONHUMAN; VALIDITY; AGONISTS; ANIMAL; BRAIN; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG STABILITY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PAIN; SYNTHESIS;

ANALGESICS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DYNORPHINS; ENDORPHINS; GLYCOLIPIDS; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; LIPOSOMES; MALE; MICE; PAIN; RECEPTORS, OPIOID, KAPPA;

EID: 84901640805     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.01.006     Document Type: Article

References (49)

1. F.L. Cardoso, D. Brites, and M.A. Brito Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches Brain Res. Rev. 64 2010 328 363
2. W.M. Pardridge The blood-brain barrier: bottleneck in brain drug development NeuroRx 2 2005 3 14 (Pubitemid 40128022)
3. W.M. Pardridge Blood-brain barrier delivery Drug Discov. Today 12 2007 54 61 (Pubitemid 46014479)
4. A. Misra, S. Ganesh, and A. Shahiwala Drug delivery to the central nervous systems: a review J. Pharm. Pharmaceut. Sci. 6 2003 252 273 (Pubitemid 37207232)
5. M.M. Patel, B.R. Goyal, S.V. Bhadada, J.S. Bhatt, and A.F. Amin Getting into the brain: approaches to enhance brain drug delivery CNS Drugs 23 2009 35 58
6. E. Garcia-Garcia, K. Andrieux, S. Gil, and P. Couvreur Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm. 298 2005 274 292 (Pubitemid 40910731)
7. J.A. MacKay, D.F. Deen, and F.C. Szoka Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating Brain Res. 28 2005 139 153 (Pubitemid 40250186)
8. V. Soni, D.V. Kohli, and S.K. Jain Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-fluorouracil J. Drug Target. 13 2005 245 250 (Pubitemid 41086289)
9. A. Beduneau, P. Saulnier, and J.P. Benoit Active targeting of brain tumors using nano-carriers Biomaterials 28 2007 4947 4967 (Pubitemid 47362345)
10. J. Qin, D. Chen, H. Hu, Q. Cui, M. Qiao, and B. Chen Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain Chem. Pharm. Bull. 55 2007 1192 1197 (Pubitemid 47344972)
11. E. Afergan, H. Epstein, R.F. Dahan, N. Koroukhov, K. Rohekar, H.D. Danenberg, and G. Golomb Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes J. Control. Release 132 2008 84 90
12. U. Schroeder, P. Sommerfeld, and B.A. Sabel Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier Peptides 19 1998 777 780 (Pubitemid 28255016)
13. R.N. Alyautdin, V.E. Petrov, K. Langer, A. Berthold, D.A. Kharkevich, and J. Kreuter Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles Pharm. Res. 14 1997 325 328 (Pubitemid 27160944)
14. J. Kreuter, P. Ramge, V. Petrov, S. Hamm, S.E. Gelperina, B. Engelhardt, R. Alyautdin, H. von Briesen, and D.J. Begley Direct evidence that polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles Pharm. Res. 20 2003 409 416 (Pubitemid 36288370)
15. I.F. Uchegbu, and S.P. Vyas Non-ionic surfactant based vesicles (niosomes) in drug delivery Int. J. Pharm. 172 1998 33 70 (Pubitemid 28430243)
16. V. Sankar, K. Ruckmani, S. Jailani, K. Siva Ganesan, and S. Sharavanan Niosome drug delivery system: advances and medical applications - an overview Pharmacol. online 2 2009 926 932
17. W.M. Pardridge Molecular regulation of blood-brain barrier GLUT1 glucose transporter J. Greenwood, D.J. Begley, M.B. Segal, New Concepts of a Blood-Brain Barrier 1995 Plenum Press New York 81 88
18. C. Dufes, F. Gaillard, I.F. Uchegbu, A.G. Schatzlein, J.C. Olivier, and J.M. Muller Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain Int. J. Pharm. 285 2004 77 85 (Pubitemid 39361538)
19. M. Bragagni, N. Mennini, C. Ghelardini, and P. Mura Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting J. Pharm. Pharmaceut. Sci. 15 2012 184 196
20. P.J. Birch, H. Rogers, A.G. Hayes, N.J. Hayward, M.B. Tyers, D.I. Scopes, A. Naylor, and D.B. Judd Neuroprotective actions of GR89696, a highly potent and selective K-opioid receptor agonist Br. J. Pharmacol. 103 1991 1819 1823
21. E. Zeynalov, M. Nemoto, P.D. Hurn, R.C. Koehler, and A. Bhardwaj Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide J. Cereb. Blood Flow Metab. 26 2006 414 420
22. R.D. Spealman, and J. Bergman Opioid modulation of the discriminative stimulus effects of cocaine: comparison of μ, κ and ∂ agonists in squirrel monkeys discriminating low doses of cocaine Behav. Pharmacol. 5 1994 21 31 (Pubitemid 24125222)
23. J.L. Neumeyer, N.K. Mello, S.S. Negus, and J.M. Bidlack Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse Pharm. Acta Helv. 74 2000 337 344 (Pubitemid 30182591)
24. P.J. Tiseo, E.B. Geller, and M.W. Adler Antinociceptive action of intracerebroventricularly administered dynorphin and other opioid peptides in the rat J. Pharmacol. Exp. Ther. 246 1988 449 453
25. G. Pugh, D.J. Mason, V. Combs, and S.P. Welch Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55, 940 in the spinal cord J. Pharmacol. Exp. Ther. 281 1997 730 737 (Pubitemid 27203805)
26. FDA Guidance For Industry, PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, Center for Drug Evaluation and Research (CDER), Rockville, MD, USA, September 2004.
27. G.A. Lewis, D. Mathieu, and R. Phan-Tan-Luu Pharmaceutical Experimental Design 1999 Marcel Dekker New York
28. C. Sánchez-Lafuente, S. Furlanetto, M. Fernández- Arévalo, J. Alvarez-Fuentes, A.M. Rabasco, M.T. Faucci, S. Pinzauti, and P. Mura Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design Int. J. Pharm. 234 2002 213 221
29. P. Mura, S. Furlanetto, M. Cirri, F. Maestrelli, A.M. Marras, and S. Pinzauti Optimization of glybenclamide tablet composition through the combined use of differential scanning calorimetry and D-optimal mixture design J. Pharm. Biomed. Anal. 37 2005 65 71 (Pubitemid 40138717)
30. S. Furlanetto, M. Cirri, F. Maestrelli, G. Corti, and P. Mura Study of formulation variables influencing the drug release rate from matrix tablets by experimental design Eur. J. Pharm. Biopharm. 62 2006 77 84 (Pubitemid 41736028)
31. N. Mennini, S. Furlanetto, F. Maestrelli, S. Pinzauti, and P. Mura Response surface methodology in the optimization of chitosan-Ca pectinate bead formulations Eur. J. Pharm. Sci. 35 2008 318 325
32. N. Mennini, S. Furlanetto, M. Cirri, and P. Mura Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-β-cyclodextrin-PVP complex Eur. J. Pharm. Sci. 80 2012 67 75
33. C. Dufes, D.G. Watson, J.C. Olivier, and I.F. Uchegbu Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting Pharm. Res. 17 2000 1250 1258
34. D. Mathieu, J. Nony, and R. Phan-Tan-Luu NEMRODW 2000 LPRAI srl Marseille, France
35. C. Rousselle, P. Clair, M. Smirnova, Y. Kolesnikov, G.W. Pasternak, S. Gac-Breton, A.R. Rees, J.M. Scherrmann, and J. Tensamani Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy J. Pharmacol. Exp. Ther. 306 2003 371 376 (Pubitemid 36734394)
36. L.S. Brady, and S.G. Holtzman Analgesic effects of intraventricular morphine and enkephalins in nondependent and morphine-dependent rats J. Pharmacol. Exp. Ther. 222 1982 190 197 (Pubitemid 12097018)
37. D. Liu, W. Chen, L. Tsai, and S. Yang Microcalorimetric studies of the effects of cholesterol on the physical stability of liposome Colloid Surf. B Biointerfaces 172 2000 57 67 (Pubitemid 30618740)
38. P. Arunothayanun, M.S. Bernard, D.Q.M. Craig, I.F. Uchegbu, and A.T. Florence The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether Int. J. Pharm. 201 2000 7 14 (Pubitemid 30364965)
39. I.F. Uchegbu, and A.G. Schatzlein Vesicles prepared from synthetic amphiphiles - polymeric vesicles and niosomes V.P. Torchilin, Nanoparticulates as Drug Carriers 2006 Imperial College Press London 108 111
40. S. Pramanick, D. Sdingodia, and V. Chandel Excipient selection in parenteral formulation development Pharma Times 45 2013 65 77
41. C. Marianecci, L. Di Marzio, F. Rinaldi, C. Celia, D. Paolino, F. Alhaique, S. Esposito, and M. Carafa Niosomes from 80s to present: the state of the art Adv. Colloid Interface Sci. 33 2013 10.1016/j.cis.2013.11.018
42. A. Pardakhty, and E. Moazeni Nano-niosomes in drug, vaccine and gene delivery: a rapid overview Nanomed. J. 1 2013 1 12
43. C. Dufes, J.M. Muller, W. Couet, J.C. Olivier, I.F. Uchegbu, and A.G. Schatzlein Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles Pharm. Res. 21 2004 101 107 (Pubitemid 38122297)
44. I.F. Uchegbu, and R. Duncan Niosomes containing N-(2-hydroxypropyl)- methacrylamide copolymer-doxorubicin (PK1): effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of biodistribution Int. J. Pharm. 155 1977 7 17
45. H. Harashima, K. Sakata, K. Funato, and H. Kiwada Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes Pharm. Res. 11 1994 402 406 (Pubitemid 24117360)
46. A. Nagayasu, K. Uchiyama, and H. Kiwada The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs Adv. Drug Deliv. Rev. 40 1999 75 87 (Pubitemid 29486605)
47. S. Short, R. Cogdill, J. Drennen, and C. Anderson Performance-based quality specifications: the relationship between process critical control parameters, critical quality attributes, and clinical performance J. Pharm. Sci. 100 2011 1566 1575
48. I.P. Kaur, A. Garg, A.K. Singla, and D. Aggarwal Vesicular systems in ocular drug delivery: an overview Int. J. Pharm. 269 2004 1 14 (Pubitemid 38035207)
49. B.V. Zlokovic, J.B. Mackic, B. Djuricic, and H. Davson Kinetic analysis of leucine-enkephalin cellular uptake at the luminal side of the blood-brain-barrier of an in situ perfused guinea-pig brain J. Neurochem. 5 1989 1333 1340 (Pubitemid 19266997)